53 results about "Essential tremor" patented technology

A method and system for providing rectangular and / or complex electrical pulses to cortical tissues of a patient for providing therapy or alleviating symptoms for at least one of tinnitus, essential tremor (ET) including Parkinson's disease, depression, or for providing improvement of functional recovery following stroke. The intracranial electrodes may be implanted on the dura, or subdurally on the pia mater of the cortical surface. The placement of the electrodes may utilize cortical sensing and / or digital imaging techniques, such as fMRI, MRI, or CT. The pulse generator system comprises implantable and external components. The pulse generator may be an implanted pulse generator (IPG) or an external stimulator coupled with an implanted stimulus-receiver. The IPG may also comprise a rechargeable battery. In one embodiment the pulse generator may also comprise a selected number of predetermined / pre-packaged programs. In one embodiment, the pulse generation may also comprise telemetry means, for remote interrogation and / or programming of said pulse generator utilizing a wide area network, such as the internet.

A peripheral nerve stimulator can be used to stimulate a peripheral nerve to treat essential tremor, Parkinson tremor, and other forms of tremor. The peripheral nerve stimulator can be either a noninvasive surface stimulator or an implanted stimulator. Stimulation can be electrical, mechanical, or chemical. Stimulation can be delivered using either an open loop system or a closed loop system with feedback.

Disclosed embodiments include an apparatus for generating a plurality of movement impairment indices from one or more kinematic signals to characterize movement disorders. Additionally we disclose methods for generating a plurality of movement impairment indices from one or more kinematic signals obtained from one or more kinematic sensors, said methods implemented in a digital computer with one or more processors in order to characterize movement disorders based on spectral analysis, regularity metrics, and time-frequency analsysis.

The present invention relates to methods for remotely and intelligently tuning movement disorder of therapy systems. The present invention still further provides methods of quantifying movement disorders for the treatment of patients who exhibit symptoms of such movement disorders including, but not limited to, Parkinson's disease and Parkinsonism, Dystonia, Chorea, and Huntington's disease, Ataxia, Tremor and Essential Tremor, Tourette syndrome, stroke, and the like. The present invention yet further relates to methods of remotely and intelligently or automatically tuning a therapy device using objective quantified movement disorder symptom data to determine the therapy setting or parameters to be transmitted and provided to the subject via his or her therapy device. The present invention also provides treatment and tuning intelligently, automatically and remotely, allowing for home monitoring of subjects.

A peripheral nerve stimulator can be used to stimulate a peripheral nerve to treat essential tremor, Parkinsonian tremor, and other forms of tremor. The stimulator can have electrodes that are placed circumferentially around the patient's wrist or arm. Specific nerves in the wrist or arm can be targeted by appropriate spacing of the electrodes. Positioning the electrodes on generally opposing sides of the target nerve can result in improved stimulation of the nerve. The stimulation pattern may alternate between the nerves. Improved stimulation algorithms can incorporate tremor feedback, external data, predictive adaptation, and long-term monitoring data.

Disclosed embodiments include an apparatus for generating a plurality of movement impairment indices from one or more kinematic signals to characterize movement disorders. Additionally we disclose methods for generating a plurality of movement impairment indices from one or more kinematic signals obtained from one or more kinematic sensors, said methods implemented in a digital computer with one or more processors in order to characterize movement disorders based on spectral analysis, regularity metrics, and time-frequency analysis.

A method for treating essential tremor or restless leg syndrome using spinal cord stimulation includes implanting a lead near a spinal cord of a patient. The lead includes a plurality of electrodes disposed on a distal end of the lead and electrically coupled to at least one contact terminal disposed on a proximal end of the lead. Electrical signals are provided from a control module coupled to the lead to stimulate a portion of the spinal cord of the patient using at least one of the electrodes. The electrical signals reduce, alleviate, or eliminate at least one adverse effect of essential tremor or restless leg syndrome.

The present invention provides novel 2-pyridinyl[7(pyridin-4-yl)pyrazolo[1,5-a]pyrimidin-3-yl]methanones with at least one substituent on both the 2- and 4-pyridinyl ring having the chemical structure of formula I: The invention further provides compositions and methods employing the novel 2-pyridinyl[7-(pyridin-4-yl)pyrazolo[1,5-a]pyrimidin-3-yl]methanones of formula I to modulate GABA and GABAA receptor physiology to elicit therapeutic responses in mammalian subjects to alleviate neurological or psychiatric disorders, including stroke, head trauma, epilepsy, pain, migraine, mood disorders, anxiety, post traumatic stress disorder, obsessive compulsive disorders, mania, bipolar disorders, schizophrenia, seizures, convulsions, tinnitus, neurodegenerative disorders including Alzheimer's disease, amyotrophic lateral sclerosis and Parkinson's disease, Huntington's chorea, depression, bipolar disorders, mania, trigeminal and other neuralgia, neuropathic pain, hypertension, cerebral ischemia, cardiac arrhythmia, myotonia, substance abuse, myoclonus, essential tremor, dyskinesia and other movement disorders, neonatal cerebral hemorrhage, and spasticity, as well as other psychiatric and neurological disorders mediated by GABA and / or GABAA receptors.

The present invention relates to a method for the prevention and treatment of essential tremor by blocking α1G T-type calcium channel, a preventive and therapeutic agent for essential tremor containing the α1G T-type calcium channel blocker as an active ingredient, and a screening method of a preventive and therapeutic agent for essential tremor by investigating α1G T-type calcium channel blocking activity. More precisely, the present invention relates to a method for the prevention and treatment of essential tremor by using α1G T-type calcium channel blocker, for which the inventors confirmed that the α1G T-type calcium channel knock out mice (α1G − / −) had resistance against essential tremor and when the T-type channel blocker was administered to the wild type mice (α1G + / +), they gained resistance against essential tremor.

The invention relates to the field of medicine, in particular to application of one or more ginkgo terpene lactone compounds or pharmacologically acceptable salts, esters, hydrates, solvates and isomers of the ginkgo terpene lactone compounds or any crystal forms, racemic mixtures and metabolites of the ginkgo terpene lactone compounds or a mixture of the ginkgo terpene lactone compounds being used as effective components to preparation of drugs and health care products for preventing and / or treating tremor. The problem of the lack of the drugs for preventing and / or treating the tremor in an existing medicine field is solved. The ginkgo terpene lactone compounds and compositions both obviously improve the state of an illness of an essential tremor model mouse, and the improvement action ofa ginkgo terpene lactone B and bilobalide composition and a bilobalide A, bilobalide B and bilobalide C composition on the essential tremor model mouse is close to that of a positive drug propranololhydrochloride. The state of the illness of essential tremor patients and vascular tremor patients is obviously improved, and no adverse reaction is found in clinical observation cases.

The invention discloses an application of a compound NSC-156529 in preparation of a T-type calcium channel antagonist. The compound inhibits the T-type calcium channel current in a dose-dependent manner through non-G-protein and non-Akt dependent ways. The T-type calcium channel antagonist drug containing the NSC-156529 structure can be constructed to be used for treating or preventing neuropsychiatric diseases (such as primary tremor, prosopalgia, cancer pain, schizophrenia, epilepsy, Parkinson's disease and depression) and reproductive diseases (such as varicocele infertility and sexual dysfunction) related to T-type calcium channel dysfunction.

The present invention relates to methods for remotely tuning treatment parameters in movement disorder therapy systems where the subject and clinician are located remotely from each other. The present invention still further provides methods of quantifying movement disorders for the treatment of patients who exhibit symptoms of such movement disorders including, but not limited to, Parkinson's disease and Parkinsonism, Dystonia, Chorea, and Huntington's disease, Ataxia, Tremor and Essential Tremor, Tourette syndrome, stroke, and the like. The present invention yet further relates to methods of remotely tuning a therapy device using objective quantified movement disorder symptom data to determine the therapy setting or parameters to be transmitted and provided to the subject via his or her therapy device. The present invention also provides treatment and tuning remotely, allowing for home monitoring of subjects.

The present invention relates to a method for the prevention and treatment of essential tremor by blocking α1G T-type calcium channel, a preventive and therapeutic agent for essential tremor containing the α1G T-type calcium channel blocker as an active ingredient, and a screening method of a preventive and therapeutic agent for essential tremor by investigating α1G T-type calcium channel blocking activity. More precisely, the present invention relates to a method for the prevention and treatment of essential tremor by using α1G T-type calcium channel blocker, for which the inventors confirmed that the α1G T-type calcium channel knock out mice (α1G− / −) had resistance against essential tremor and when the T-type channel blocker was administered to the wild type mice (α1G+ / +), they gained resistance against essential tremor.

The present invention relates to methods for remotely tuning treatment parameters in movement disorder therapy systems where the subject and clinician are located remotely from each other. The present invention still further provides methods of quantifying movement disorders for the treatment of patients who exhibit symptoms of such movement disorders including, but not limited to, Parkinson's disease and Parkinsonism, Dystonia, Chorea, and Huntington's disease, Ataxia, Tremor and Essential Tremor, Tourette syndrome, stroke, and the like. The present invention yet further relates to methods of remotely tuning a therapy device using objective quantified movement disorder symptom data to determine the therapy setting or parameters to be transmitted and provided to the subject via his or her therapy device. The present invention also provides treatment and tuning remotely, allowing for home monitoring of subjects.